Mechanism of AF9 (MLLT3)-Partner Dissociation in Mixed-Lineage Leukemia-Rearranged Leukemia

混合谱系白血病重排白血病中AF9(MLLT3)-伴侣解离的机制

阅读:1

Abstract

Chromosomal rearrangements involving the mixed-lineage leukemia (MLL) gene drive aggressive leukemias with a poor prognosis. AF9 (MLLT3), a YEATS family protein, is a core component of transcriptional and epigenetic regulatory complexes essential for hematopoietic stem cell maintenance. In MLL-rearranged leukemia, the MLL-AF9 fusion protein aberrantly recruits transcriptional and epigenetic modifiers, including DOT1L, BCOR, and CBX8, disrupting normal hematopoietic gene regulation. Despite the importance of these interactions, the molecular mechanisms underlying AF9-partner(s) binding and their dissociation remain unclear. Here, we employed Protein-Protein Interaction-Gaussian accelerated Molecular Dynamics (PPI-GaMD) simulations to probe the dissociation pathways of AF9-bound peptides. Free-energy landscapes revealed that the dissociation process proceeds in a stepwise manner through metastable intermediates. Dissociation predominantly occurred through channel 1, a broad electrostatically asymmetric face of AF9. Consistent with the experimental findings, DOT1L formed the most stable complex with AF9, followed by CBX8 and then BCOR. Distinct intermediate conformations and interaction patterns were observed for each partner, reflecting their differential binding stabilities. Partner release was primarily driven by electrostatic interactions, while metastable intermediates were stabilized by hydrophobic contacts. The extended hydrophobic surface of DOT1L accounted for its enhanced binding, evident from its dominant van der Waals contribution. Clustering analysis identified dominant intermediate conformations that highlight critical steps in peptide dissociation and provide structural templates for inhibitor design. These metastable states represent druggable conformations that can be leveraged in structure-based screening, offering a foundation for targeted therapies in MLL-rearranged leukemias.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。